Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab IV maintenance therapy in pediatric moderate to severe ulcerative colitis
CTR20221910Phase 3Completed
- Sponsor
- Takeda
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of vedolizumab in autoimmune colitis, sponsored by Takeda. Started May 2022; status: completed.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20221910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221910.